

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	30.0	100.1	(67.6-143.0)	Male	15	19.0	79.1	(44.2-130.5)
Female	7	10.8	64.9	(26.0-133.8)	Female	16	14.7	108.9	(62.2-176.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	5.3	169.4	(77.3-321.7)	Male	6	5.6	107.3	(39.2-233.5)
Female	2	4.5	nc	(nc-nc)	Female	5	4.6	109.8	(35.4-256.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	26	16.6	156.4	(102.2-229.2)
Female	123	112.5	109.3	(90.9-130.5)	Female	15	14.2	105.9	(59.2-174.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.8	nc	(nc-nc)	Male	9	12.8	70.0	(32.0-133.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	32	32.1	99.7	(68.2-140.8)	Female	7	10.3	68.2	(27.3-140.4)
Female	30	32.1	93.6	(63.1-133.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	10.0	109.8	(54.8-196.5)
Male	4	7.8	nc	(nc-nc)	Female	13	10.4	124.6	(66.3-213.1)
Female	1	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	99	102.1	97.0	(78.8-118.1)
Male	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.8	nc	(nc-nc)	Male	5	6.9	72.9	(23.5-170.0)
<u>Kidney & Renal Pelvis</u>					Female	5	4.0	124.4	(40.1-290.3)
Male	18	15.5	116.0	(68.7-183.3)	<u>Testis</u>				
Female	8	9.2	87.1	(37.5-171.7)	Male	4	3.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.3	nc	(nc-nc)	Male	11	6.9	159.4	(79.5-285.2)
Female	1	1.4	nc	(nc-nc)	Female	28	20.2	138.5	(92.0-200.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	11.5	156.1	(92.4-246.6)	Female	31	25.7	120.7	(82.0-171.4)
Female	7	8.4	83.2	(33.3-171.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	398	386.9	102.9	(93.0-113.5)
Male	8	9.6	83.1	(35.8-163.7)	Female	399	387.5	103.0	(93.1-113.6)
Female	3	3.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	47	54.4	86.5	(63.5-115.0)					
Female	55	56.8	96.8	(72.9-126.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;